Although this study found that inhibition of SREBP-1 may enhance the therapeutic effect of sunitinib in RCC patients, the role of statins, visfatin, and their combination therapy strategies in obesity situations in vivo still needs to be further studied. This evidence concerns the gene NAMPT and renal cell carcinoma.